Biosenta Inc.
ZRO
CNSX
| Weiss Ratings | ZRO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ZRO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ZRO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.29 | |||
| Price History | ZRO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 6.67% | |||
| 60-Day Total Return | 0.00% | |||
| 90-Day Total Return | 146.15% | |||
| Year to Date Total Return | -15.79% | |||
| 1-Year Total Return | -72.88% | |||
| 2-Year Total Return | -60.00% | |||
| 3-Year Total Return | -40.74% | |||
| 5-Year Total Return | 100.00% | |||
| 52-Week High % Change | -73.33% | |||
| 52-Week Low % Change | 190.91% | |||
| Price | ZRO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.60 | |||
| 52-Week Low Price | $0.06 | |||
| 52-Week Low Price (Date) | Oct 17, 2024 | |||
| 52-Week High Price (Date) | Mar 07, 2024 | |||
| Valuation | ZRO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 3.64M | |||
| Enterprise Value | 7.73M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.06 | |||
| Earnings Per Share Growth | -60.69% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -0.88 | |||
| Enterprise Value/Revenue (TTM) | 19,340.02 | |||
| Price | $0.16 | |||
| Enterprise Value/EBITDA (TTM) | -12.34 | |||
| Enterprise Value/EBIT | -9.54 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ZRO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 31.89M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ZRO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 416 410 2019 | |||
| Address | 18 Wynford Drive Toronto, ON M3C 3S2 | |||
| Website | www.biosenta.com | |||
| Country | Canada | |||
| Year Founded | 1986 | |||
| Profitability | ZRO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -202,650.00% | |||
| Profit Margin | -409,275.00% | |||
| Management Effectiveness | ZRO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -619.72% | |||
| Return on Equity | -- | |||
| Income Statement | ZRO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 400.00 | |||
| Total Revenue (TTM) | 400.00 | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | 300.00 | |||
| EBITDA (TTM) | -626.90K | |||
| EBIT (TTM) | -810.60K | |||
| Net Income (TTM) | -1.64M | |||
| Net Income Avl. to Common (TTM) | -1.64M | |||
| Total Revenue Growth (Q YOY) | -48,800.00% | |||
| Earnings Growth (Q YOY) | 86.56% | |||
| EPS Diluted (TTM) | -0.06 | |||
| EPS Diluted Growth (Q YOY) | 85.09% | |||
| Balance Sheet | ZRO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 6.30K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 74.70K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -5.83M | |||
| Current Ratio (Q) | 0.040 | |||
| Book Value Per Share (Q) | -$0.18 | |||
| Total Assets (Q) | 84.00K | |||
| Total Current Liabilities (Q) | 1.88M | |||
| Total Debt (Q) | 4.11M | |||
| Total Liabilities (Q) | 5.91M | |||
| Total Common Equity (Q) | -5.83M | |||
| Cash Flow | ZRO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 574.30K | |||
| Net Change in Cash (TTM) | 1.10K | |||
| Levered Free Cash Flow (TTM) | -919.90K | |||
| Cash from Operations (TTM) | -573.10K | |||
